Dodge & Cox Alnylam Pharmaceuticals, Inc. Transaction History

Dodge & Cox

$163 Billion
Q1 2024

A detailed history of Dodge & Cox transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Dodge & Cox holds 3,811,480 shares of ALNY stock, worth $566 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares

3,811,480

Previous 3,674,310 3.73%

Holding current value

$566 Million

Previous $703 Million 19.01%

% of portfolio

0.35%

Previous 0.47%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$146.51 - $198.2 $20.1 Million - $27.2 Million	137,170 Added 3.73%	3,811,480 $570 Million
Q4 2023 Feb 15, 2024	SELL	$151.41 - $196.57 $11 Million - $14.3 Million	-72,845 Reduced 1.94%	3,674,310 $703 Million
Q3 2023 Nov 14, 2023	SELL	$170.77 - $211.65 $7.24 Million - $8.97 Million	-42,370 Reduced 1.12%	3,747,155 $664 Million
Q2 2023 Aug 14, 2023	SELL	$185.01 - $212.05 $19.4 Million - $22.3 Million	-105,010 Reduced 2.7%	3,789,525 $720 Million
Q1 2023 May 12, 2023	SELL	$182.66 - $235.53 $127 Million - $164 Million	-696,247 Reduced 15.17%	3,894,535 $780 Million

Q4 2022 Feb 14, 2023	SELL	$185.53 - $241.31 $55.4 Million - $72 Million	-298,515 Reduced 6.11%	4,590,782 $1.09 Billion
Q3 2022 Nov 10, 2022	SELL	$138.54 - $232.0 $51.2 Million - $85.8 Million	-369,659 Reduced 7.03%	4,889,297 $979 Million
Q2 2022 Aug 12, 2022	SELL	$120.42 - $169.29 $26.1 Million - $36.7 Million	-216,712 Reduced 3.96%	5,258,956 $767 Million
Q1 2022 May 13, 2022	BUY	$127.18 - $173.91 $5.67 Million - $7.76 Million	44,600 Added 0.82%	5,475,668 $894 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $9.41 Million - $12.3 Million	58,968 Added 1.1%	5,431,068 $921 Million
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $7.11 Million - $8.7 Million	-41,901 Reduced 0.77%	5,372,100 $1.01 Billion
Q2 2021 Aug 13, 2021	BUY	$128.63 - $176.89 $141 Million - $193 Million	1,092,374 Added 25.28%	5,414,001 $918 Million
Q1 2021 May 14, 2021	SELL	$126.83 - $175.69 $40.4 Million - $55.9 Million	-318,286 Reduced 6.86%	4,321,627 $610 Million
Q4 2020 Feb 11, 2021	SELL	$122.97 - $147.0 $4.64 Million - $5.54 Million	-37,700 Reduced 0.81%	4,639,913 $603 Million
Q3 2020 Nov 13, 2020	SELL	$121.19 - $165.49 $3.16 Million - $4.31 Million	-26,058 Reduced 0.55%	4,677,613 $681 Million
Q2 2020 Aug 13, 2020	SELL	$104.21 - $156.44 $40.6 Million - $61 Million	-389,675 Reduced 7.65%	4,703,671 $697 Million
Q1 2020 May 14, 2020	SELL	$93.12 - $133.99 $14.7 Million - $21.2 Million	-157,975 Reduced 3.01%	5,093,346 $554 Million
Q4 2019 Feb 13, 2020	SELL	$74.51 - $124.23 $4.51 Million - $7.51 Million	-60,480 Reduced 1.14%	5,251,321 $605 Million
Q3 2019 Nov 13, 2019	BUY	$70.9 - $87.82 $4.98 Million - $6.17 Million	70,300 Added 1.34%	5,311,801 $427 Million
Q2 2019 Aug 13, 2019	BUY	$65.86 - $92.79 $16 Million - $22.6 Million	243,500 Added 4.87%	5,241,501 $380 Million
Q1 2019 May 14, 2019	BUY	$72.76 - $93.45 $22.4 Million - $28.8 Million	307,750 Added 6.56%	4,998,001 $467 Million
Q4 2018 Feb 14, 2019	BUY	$62.67 - $88.33 $2.17 Million - $3.06 Million	34,600 Added 0.74%	4,690,251 $342 Million
Q3 2018 Nov 14, 2018	BUY	$87.52 - $122.67 $83,144 - $116,536	950 Added 0.02%	4,655,651 $407 Million
Q2 2018 Aug 14, 2018	SELL	$88.31 - $107.8 $3.37 Million - $4.11 Million	-38,140 Reduced 0.81%	4,654,701 $458 Million
Q1 2018 May 14, 2018	SELL	$115.92 - $148.54 $410 Million - $526 Million	-3,538,754 Reduced 42.99%	4,692,841 $559 Million
Q4 2017 Feb 14, 2018	SELL	$114.49 - $139.98 $104 Million - $127 Million	-909,900 Reduced 9.95%	8,231,595 $1.05 Billion
Q3 2017 Nov 13, 2017	BUY	$72.53 - $118.27 $663 Million - $1.08 Billion	9,141,495	9,141,495 $1.07 Billion

Others Institutions Holding ALNY

# of Institutions

584

Shares Held

104M

Call Options Held

2.82M

Put Options Held

1.75M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $18.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dodge & Cox, based on Form 13F filings with the SEC.

News

Stay updated on Dodge & Cox with notifications on news.

Account